Intrinsic value of Inogen - INGN

Previous Close

$136.43

  Intrinsic Value

$92.74

stock screener

  Rating & Target

sell

-32%

Previous close

$136.43

 
Intrinsic value

$92.74

 
Up/down potential

-32%

 
Rating

sell

We calculate the intrinsic value of INGN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  51.60
  46.94
  42.75
  38.97
  35.57
  32.52
  29.77
  27.29
  25.06
  23.05
  21.25
  19.62
  18.16
  16.85
  15.66
  14.59
  13.64
  12.77
  11.99
  11.29
  10.67
  10.10
  9.59
  9.13
  8.72
  8.35
  8.01
  7.71
  7.44
  7.19
Revenue, $m
  378
  556
  793
  1,102
  1,494
  1,980
  2,570
  3,271
  4,091
  5,034
  6,103
  7,301
  8,627
  10,080
  11,659
  13,361
  15,182
  17,121
  19,175
  21,341
  23,617
  26,002
  28,495
  31,097
  33,808
  36,629
  39,563
  42,614
  45,784
  49,078
Variable operating expenses, $m
  335
  493
  703
  976
  1,323
  1,754
  2,275
  2,896
  3,622
  4,456
  5,403
  6,463
  7,636
  8,923
  10,320
  11,826
  13,439
  15,155
  16,973
  18,890
  20,905
  23,016
  25,223
  27,526
  29,925
  32,423
  35,020
  37,720
  40,526
  43,442
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  335
  493
  703
  976
  1,323
  1,754
  2,275
  2,896
  3,622
  4,456
  5,403
  6,463
  7,636
  8,923
  10,320
  11,826
  13,439
  15,155
  16,973
  18,890
  20,905
  23,016
  25,223
  27,526
  29,925
  32,423
  35,020
  37,720
  40,526
  43,442
Operating income, $m
  43
  63
  90
  126
  171
  227
  294
  375
  469
  577
  701
  838
  991
  1,158
  1,339
  1,534
  1,744
  1,966
  2,202
  2,451
  2,712
  2,986
  3,272
  3,571
  3,882
  4,206
  4,543
  4,894
  5,258
  5,636
EBITDA, $m
  51
  75
  107
  148
  201
  266
  345
  440
  550
  677
  821
  982
  1,160
  1,355
  1,567
  1,796
  2,041
  2,302
  2,578
  2,869
  3,175
  3,496
  3,831
  4,181
  4,545
  4,924
  5,319
  5,729
  6,155
  6,598
Interest expense (income), $m
  0
  0
  1
  3
  6
  9
  13
  18
  24
  32
  40
  50
  61
  74
  87
  102
  119
  137
  156
  176
  197
  220
  244
  268
  294
  322
  350
  379
  410
  442
  475
Earnings before tax, $m
  43
  62
  87
  120
  162
  214
  276
  351
  438
  537
  651
  777
  917
  1,070
  1,236
  1,415
  1,607
  1,811
  2,026
  2,253
  2,492
  2,742
  3,004
  3,277
  3,561
  3,857
  4,164
  4,484
  4,816
  5,161
Tax expense, $m
  12
  17
  24
  32
  44
  58
  75
  95
  118
  145
  176
  210
  248
  289
  334
  382
  434
  489
  547
  608
  673
  740
  811
  885
  961
  1,041
  1,124
  1,211
  1,300
  1,394
Net income, $m
  31
  45
  64
  88
  118
  156
  202
  256
  319
  392
  475
  568
  670
  781
  903
  1,033
  1,173
  1,322
  1,479
  1,645
  1,819
  2,002
  2,193
  2,392
  2,599
  2,815
  3,040
  3,273
  3,516
  3,768

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  205
  301
  430
  598
  810
  1,074
  1,394
  1,774
  2,218
  2,730
  3,310
  3,959
  4,679
  5,467
  6,323
  7,245
  8,233
  9,285
  10,399
  11,573
  12,807
  14,101
  15,453
  16,864
  18,334
  19,864
  21,455
  23,109
  24,828
  26,615
Adjusted assets (=assets-cash), $m
  205
  301
  430
  598
  810
  1,074
  1,394
  1,774
  2,218
  2,730
  3,310
  3,959
  4,679
  5,467
  6,323
  7,245
  8,233
  9,285
  10,399
  11,573
  12,807
  14,101
  15,453
  16,864
  18,334
  19,864
  21,455
  23,109
  24,828
  26,615
Revenue / Adjusted assets
  1.844
  1.847
  1.844
  1.843
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
  1.844
Average production assets, $m
  37
  54
  78
  108
  146
  194
  252
  321
  401
  493
  598
  716
  845
  988
  1,143
  1,309
  1,488
  1,678
  1,879
  2,091
  2,314
  2,548
  2,793
  3,048
  3,313
  3,590
  3,877
  4,176
  4,487
  4,810
Working capital, $m
  31
  46
  66
  91
  124
  164
  213
  271
  340
  418
  507
  606
  716
  837
  968
  1,109
  1,260
  1,421
  1,592
  1,771
  1,960
  2,158
  2,365
  2,581
  2,806
  3,040
  3,284
  3,537
  3,800
  4,073
Total debt, $m
  25
  59
  105
  165
  240
  334
  448
  583
  742
  924
  1,130
  1,362
  1,618
  1,898
  2,203
  2,531
  2,883
  3,257
  3,654
  4,072
  4,511
  4,972
  5,453
  5,956
  6,479
  7,024
  7,590
  8,179
  8,791
  9,427
Total liabilities, $m
  73
  107
  153
  213
  289
  382
  496
  632
  790
  972
  1,178
  1,410
  1,666
  1,946
  2,251
  2,579
  2,931
  3,305
  3,702
  4,120
  4,559
  5,020
  5,501
  6,004
  6,527
  7,072
  7,638
  8,227
  8,839
  9,475
Total equity, $m
  132
  194
  277
  385
  522
  692
  897
  1,142
  1,429
  1,758
  2,132
  2,550
  3,013
  3,520
  4,072
  4,666
  5,302
  5,979
  6,697
  7,453
  8,248
  9,081
  9,952
  10,860
  11,807
  12,792
  13,817
  14,882
  15,990
  17,140
Total liabilities and equity, $m
  205
  301
  430
  598
  811
  1,074
  1,393
  1,774
  2,219
  2,730
  3,310
  3,960
  4,679
  5,466
  6,323
  7,245
  8,233
  9,284
  10,399
  11,573
  12,807
  14,101
  15,453
  16,864
  18,334
  19,864
  21,455
  23,109
  24,829
  26,615
Debt-to-equity ratio
  0.190
  0.310
  0.380
  0.430
  0.460
  0.480
  0.500
  0.510
  0.520
  0.530
  0.530
  0.530
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
Adjusted equity ratio
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644
  0.644

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  31
  45
  64
  88
  118
  156
  202
  256
  319
  392
  475
  568
  670
  781
  903
  1,033
  1,173
  1,322
  1,479
  1,645
  1,819
  2,002
  2,193
  2,392
  2,599
  2,815
  3,040
  3,273
  3,516
  3,768
Depreciation, amort., depletion, $m
  8
  12
  16
  22
  30
  40
  51
  65
  81
  99
  120
  143
  169
  198
  229
  262
  298
  336
  376
  418
  463
  510
  559
  610
  663
  718
  775
  835
  897
  962
Funds from operations, $m
  39
  57
  80
  110
  148
  196
  253
  321
  400
  492
  595
  711
  839
  979
  1,131
  1,295
  1,471
  1,657
  1,855
  2,063
  2,282
  2,512
  2,751
  3,001
  3,262
  3,533
  3,815
  4,108
  4,413
  4,730
Change in working capital, $m
  11
  15
  20
  26
  33
  40
  49
  58
  68
  78
  89
  99
  110
  121
  131
  141
  151
  161
  170
  180
  189
  198
  207
  216
  225
  234
  244
  253
  263
  273
Cash from operations, $m
  29
  42
  60
  84
  116
  155
  204
  263
  332
  413
  506
  611
  729
  858
  1,000
  1,154
  1,319
  1,496
  1,684
  1,884
  2,093
  2,314
  2,544
  2,786
  3,037
  3,299
  3,572
  3,855
  4,150
  4,456
Maintenance CAPEX, $m
  -5
  -7
  -11
  -16
  -22
  -29
  -39
  -50
  -64
  -80
  -99
  -120
  -143
  -169
  -198
  -229
  -262
  -298
  -336
  -376
  -418
  -463
  -510
  -559
  -610
  -663
  -718
  -775
  -835
  -897
New CAPEX, $m
  -13
  -17
  -23
  -30
  -38
  -48
  -58
  -69
  -80
  -92
  -105
  -117
  -130
  -142
  -155
  -167
  -179
  -190
  -201
  -212
  -223
  -234
  -244
  -255
  -266
  -276
  -288
  -299
  -311
  -323
Cash from investing activities, $m
  -18
  -24
  -34
  -46
  -60
  -77
  -97
  -119
  -144
  -172
  -204
  -237
  -273
  -311
  -353
  -396
  -441
  -488
  -537
  -588
  -641
  -697
  -754
  -814
  -876
  -939
  -1,006
  -1,074
  -1,146
  -1,220
Free cash flow, $m
  11
  17
  26
  39
  56
  78
  107
  144
  188
  241
  303
  374
  456
  547
  648
  759
  879
  1,009
  1,148
  1,295
  1,452
  1,617
  1,790
  1,972
  2,162
  2,360
  2,566
  2,781
  3,004
  3,236
Issuance/(repayment) of debt, $m
  25
  34
  46
  60
  76
  94
  114
  135
  158
  182
  206
  231
  256
  281
  305
  329
  352
  374
  396
  418
  439
  460
  481
  502
  523
  545
  566
  589
  612
  636
Issuance/(repurchase) of shares, $m
  14
  17
  19
  20
  19
  14
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  39
  51
  65
  80
  95
  108
  118
  135
  158
  182
  206
  231
  256
  281
  305
  329
  352
  374
  396
  418
  439
  460
  481
  502
  523
  545
  566
  589
  612
  636
Total cash flow (excl. dividends), $m
  50
  68
  91
  118
  150
  186
  225
  279
  346
  423
  509
  605
  712
  827
  953
  1,087
  1,231
  1,383
  1,544
  1,714
  1,891
  2,077
  2,272
  2,474
  2,685
  2,905
  3,133
  3,370
  3,616
  3,872
Retained Cash Flow (-), $m
  -45
  -62
  -83
  -108
  -137
  -170
  -206
  -245
  -286
  -329
  -374
  -418
  -463
  -508
  -551
  -594
  -636
  -677
  -717
  -756
  -795
  -833
  -871
  -909
  -947
  -985
  -1,025
  -1,065
  -1,107
  -1,150
Prev. year cash balance distribution, $m
  140
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  145
  6
  8
  10
  13
  16
  19
  34
  60
  93
  136
  187
  248
  320
  401
  493
  594
  706
  827
  957
  1,096
  1,245
  1,401
  1,566
  1,739
  1,919
  2,108
  2,304
  2,509
  2,722
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  139
  6
  7
  9
  10
  12
  13
  21
  34
  49
  64
  80
  94
  107
  118
  125
  129
  130
  127
  122
  113
  103
  92
  80
  68
  56
  45
  36
  27
  20
Current shareholders' claim on cash, %
  98.4
  97.2
  96.2
  95.5
  95.1
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8
  94.8

Inogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company's Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.

FINANCIAL RATIOS  of  Inogen (INGN)

Valuation Ratios
P/E Ratio 132.5
Price to Sales 13.7
Price to Book 15.3
Price to Tangible Book
Price to Cash Flow 89.7
Price to Free Cash Flow 95.9
Growth Rates
Sales Growth Rate 27.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate -7.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 11.2%
Ret/ On Assets - 3 Yr. Avg. 8.5%
Return On Total Capital 13.3%
Ret/ On T. Cap. - 3 Yr. Avg. 10.1%
Return On Equity 13.3%
Return On Equity - 3 Yr. Avg. 10.3%
Asset Turnover 1.1
Profitability Ratios
Gross Margin 47.8%
Gross Margin - 3 Yr. Avg. 48.4%
EBITDA Margin 18.2%
EBITDA Margin - 3 Yr. Avg. 18.6%
Operating Margin 11.3%
Oper. Margin - 3 Yr. Avg. 10.2%
Pre-Tax Margin 11.3%
Pre-Tax Margin - 3 Yr. Avg. 9.9%
Net Profit Margin 10.3%
Net Profit Margin - 3 Yr. Avg. 8%
Effective Tax Rate 8.7%
Eff/ Tax Rate - 3 Yr. Avg. 19.6%
Payout Ratio 0%

INGN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the INGN stock intrinsic value calculation we used $249.438 million for the last fiscal year's total revenue generated by Inogen. The default revenue input number comes from 0001 income statement of Inogen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our INGN stock valuation model: a) initial revenue growth rate of 51.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for INGN is calculated based on our internal credit rating of Inogen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Inogen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of INGN stock the variable cost ratio is equal to 88.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for INGN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Inogen.

Corporate tax rate of 27% is the nominal tax rate for Inogen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the INGN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for INGN are equal to 9.8%.

Life of production assets of 2.1 years is the average useful life of capital assets used in Inogen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for INGN is equal to 8.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $227.041 million for Inogen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 21.35 million for Inogen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Inogen at the current share price and the inputted number of shares is $2.9 billion.

RELATED COMPANIES Price Int.Val. Rating
RMD ResMed 115.16 66.17  sell
AHPI Allied Healthc 1.97 1.01  str.sell
IVC Invacare 5.22 7.95  str.sell
GTLS Chart Industri 61.90 45.82  sell
ELMD Electromed 5.50 3.00  sell
MASI Masimo 111.41 135.72  hold

COMPANY NEWS

▶ Hedge Funds Are Crazy About Inogen Inc (INGN)   [Dec-15-18 03:38AM  Insider Monkey]
▶ Steven Cohen Takes an Interest in Inogen   [Nov-30-18 12:29PM  GuruFocus.com]
▶ 10 Deeply Discounted Stocks to Buy   [Nov-14-18 03:56PM  Kiplinger]
▶ Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar   [Nov-13-18 12:25PM  Investor's Business Daily]
▶ Inogen: 3Q Earnings Snapshot   [05:43PM  Associated Press]
▶ Top Stock Picks for the Week of November 5th   [Nov-05-18 02:53PM  Zacks]
▶ Varian Medical (VAR) Jumps: Stock Rises 7.7%   [Oct-25-18 09:44AM  Zacks]
▶ Inogen Announces Management Changes   [Aug-28-18 04:05PM  Business Wire]
▶ Inogen: 2Q Earnings Snapshot   [06:07PM  Associated Press]
▶ This Top-Rated Medtech Just Crushed Second-Quarter Views   [05:11PM  Investor's Business Daily]
▶ Why Inogen Inc (NASDAQ:INGN) Could Be A Buy   [Jun-25-18 08:34AM  Simply Wall St.]
▶ 7 A-Rated Stocks to Buy for the Second Half of 2018   [Jun-08-18 03:00PM  InvestorPlace]
▶ After-hours buzz: CGNX, AKAM & more   [Apr-30-18 05:37PM  CNBC]
▶ Inogen: 1Q Earnings Snapshot   [04:36PM  Associated Press]
▶ Inogen, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Inogen reports 4Q loss   [Feb-27-18 07:23PM  Associated Press]
▶ Inogen, Inc. to Host Earnings Call   [12:50PM  ACCESSWIRE]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.